Ebix, Inc. (EBIX) Reaches $81.75 52-Week High; Cleveland Biolabs (CBLI) Shorts Down By 13.67%

January 14, 2018 - By Maria Brooks

Cleveland Biolabs Incorporated (NASDAQ:CBLI) had a decrease of 13.67% in short interest. CBLI’s SI was 22,100 shares in January as released by FINRA. Its down 13.67% from 25,600 shares previously. With 20,600 avg volume, 1 days are for Cleveland Biolabs Incorporated (NASDAQ:CBLI)’s short sellers to cover CBLI’s short positions. The SI to Cleveland Biolabs Incorporated’s float is 0.77%. The stock decreased 3.71% or $0.15 during the last trading session, reaching $3.89. About 26,472 shares traded. Cleveland BioLabs, Inc. (NASDAQ:CBLI) has risen 63.33% since January 14, 2017 and is uptrending. It has outperformed by 46.63% the S&P500.

The stock of Ebix, Inc. (NASDAQ:EBIX) hit a new 52-week high and has $84.20 target or 3.00% above today’s $81.75 share price. The 5 months bullish chart indicates low risk for the $2.57 billion company. The 1-year high was reported on Jan, 14 by Barchart.com. If the $84.20 price target is reached, the company will be worth $77.13 million more. The stock increased 0.68% or $0.55 during the last trading session, reaching $81.75. About 108,097 shares traded. Ebix, Inc. (NASDAQ:EBIX) has risen 21.95% since January 14, 2017 and is uptrending. It has outperformed by 5.25% the S&P500.




Among 2 analysts covering Ebix (NASDAQ:EBIX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ebix had 4 analyst reports since August 11, 2015 according to SRatingsIntel. Zacks upgraded the shares of EBIX in report on Tuesday, August 11 to “Hold” rating. William Blair initiated the stock with “Buy” rating in Thursday, September 28 report. Craig Hallum maintained Ebix, Inc. (NASDAQ:EBIX) rating on Thursday, November 9. Craig Hallum has “Buy” rating and $87.0 target.

Ebix, Inc. provides software and e-commerce solutions to insurance, finance, and healthcare industries. The company has market cap of $2.57 billion. It offers software development, customization, and consulting services to various entities in the insurance industry, including carriers, brokers, exchanges, and standard making bodies. It has a 26.46 P/E ratio. The firm operates data exchanges in the areas of life insurance, annuities, employee health benefits, risk management, workers compensation, insurance underwriting, and property and casualty insurance.

Analysts await Ebix, Inc. (NASDAQ:EBIX) to report earnings on February, 27. They expect $0.75 EPS, down 1.32% or $0.01 from last year’s $0.76 per share. EBIX’s profit will be $23.59 million for 27.25 P/E if the $0.75 EPS becomes a reality. After $0.76 actual EPS reported by Ebix, Inc. for the previous quarter, Wall Street now forecasts -1.32% negative EPS growth.

Investors sentiment increased to 1.23 in 2017 Q3. Its up 0.14, from 1.09 in 2017Q2. It improved, as 23 investors sold Ebix, Inc. shares while 42 reduced holdings. 27 funds opened positions while 53 raised stakes. 19.27 million shares or 1.10% less from 19.48 million shares in 2017Q2 were reported. State Common Retirement Fund reported 0% of its portfolio in Ebix, Inc. (NASDAQ:EBIX). State Board Of Administration Of Florida Retirement System reported 13,999 shares. Atwood And Palmer has invested 3.07% in Ebix, Inc. (NASDAQ:EBIX). Renaissance Grp Lc holds 0.01% of its portfolio in Ebix, Inc. (NASDAQ:EBIX) for 6,197 shares. Virginia Retirement Sys Et Al stated it has 0.01% of its portfolio in Ebix, Inc. (NASDAQ:EBIX). Us Commercial Bank De invested in 2,991 shares or 0% of the stock. Art Lc invested in 23,000 shares or 0.08% of the stock. Riverhead Capital Ltd Llc reported 0.01% of its portfolio in Ebix, Inc. (NASDAQ:EBIX). Villere St Denis J Limited Liability reported 912,821 shares. Balyasny Asset Mngmt Lc stated it has 0% of its portfolio in Ebix, Inc. (NASDAQ:EBIX). 454,102 were reported by Northern Trust. Legal General Group Public Ltd Co has invested 0% of its portfolio in Ebix, Inc. (NASDAQ:EBIX). Parametric Portfolio Assocs Ltd Com holds 0% of its portfolio in Ebix, Inc. (NASDAQ:EBIX) for 46,175 shares. Royal Commercial Bank Of Canada, a Ontario – Canada-based fund reported 9,129 shares. Parkside Finance Bancshares Tru has 195 shares for 0.01% of their portfolio.

Investors sentiment decreased to 1.5 in 2017 Q3. Its down 8.50, from 10 in 2017Q2. It dived, as 2 investors sold Cleveland BioLabs, Inc. shares while 2 reduced holdings. 3 funds opened positions while 3 raised stakes. 438,124 shares or 57.55% less from 1.03 million shares in 2017Q2 were reported. The New York-based Morgan Stanley has invested 0% in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Financial Bank Of America De invested in 100 shares or 0% of the stock. Citadel Advsr Ltd Com accumulated 10,032 shares. Geode Limited Company owns 16,688 shares. Us Savings Bank De holds 0% or 100 shares in its portfolio. Moreover, Royal National Bank & Trust Of Canada has 0% invested in Cleveland BioLabs, Inc. (NASDAQ:CBLI) for 1 shares. Thompson Davis And Inc stated it has 1,334 shares or 0.01% of all its holdings. Blackrock stated it has 14,292 shares. Renaissance Technology Limited Liability Com reported 0% in Cleveland BioLabs, Inc. (NASDAQ:CBLI). Commercial Bank Of Montreal Can accumulated 31 shares. Wells Fargo And Mn holds 0% or 450 shares in its portfolio. Vanguard Inc accumulated 170,088 shares. Group One Trading Lp accumulated 68 shares. Winfield stated it has 500 shares. Deutsche Comml Bank Ag has 0% invested in Cleveland BioLabs, Inc. (NASDAQ:CBLI) for 3,804 shares.

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The company has market cap of $43.88 million. The companyÂ’s advanced product candidate is entolimod, a Toll-like receptor 5 agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It currently has negative earnings. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: